Am. J. Respir. Crit. Care Med., Volume 162, Number 6, December 2000, 2241-2245

Multiple Combination Bactericidal Antibiotic Testing for Patients with Cystic Fibrosis Infected with Multiresistant Strains of Pseudomonas aeruginosa

BIANCA J. LANG, SHAWN D. AARON, WENDY FERRIS, PAUL C. HEBERT, and NONI E. MACDONALD

Departments of Medicine and Pediatrics, University of Ottawa, Ottawa, Ontario; and Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

We developed a rapid in vitro antibiotic susceptibility test to screen double- and triple-antibiotic combinations for bactericidal activity against 75 multiresistant Pseudomonas aeruginosa isolates referred from 44 cystic fibrosis (CF) patients. When used alone, the most effective intravenous antibiotic, meropenem, was bactericidal against only 44% of the isolates. High-dose tobramycin (200 µg/ml; concentrations achievable by aerosol administration) was bactericidal against 72% of isolates. Adding a second antibiotic significantly improved bactericidal activity. The most effective double-antibiotic combinations contained high-dose tobramycin plus meropenem, piperacillin/tazobactam, or ciprofloxacin, and were bactericidal against 88 to 94% of the isolates. Excluding high-dose tobramycin, the most effective intravenous double-antibiotic combinations contained meropenem plus ciprofloxacin, tobramycin (4 µg/ml), or cefipime, and were bactericidal against 85%, 71%, and 70% of isolates, respectively. Adding a third antibiotic did not significantly improve inhibition in vitro. We conclude that double-antibiotic combinations containing meropenem or high-dose tobramycin show the best bactericidal activity in vitro against multiresistant strains of P. aeruginosa. Addition of a third antibiotic to these double-antibiotic combinations may be unnecessary.

This article has been cited by other articles:

				J. E. Foweraker, C. R. Laughton, D. F. Brown, and D. Bilton Comparison of Methods To Test Antibiotic Combinations against Heterogeneous Populations of Multiresistant Pseudomonas aeruginosa from Patients with Acute Infective Exacerbations in Cystic Fibrosis Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4809 - 4815. [Abstract] [Full Text] [PDF]

				G Meachery, A De Soyza, A Nicholson, G Parry, A Hasan, K Tocewicz, T Pillay, S Clark, J L Lordan, S Schueler, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort Thorax, August 1, 2008; 63(8): 725 - 731. [Abstract] [Full Text] [PDF]

				J S. Elborn Identification and management of unusual pathogens in cystic fibrosis J R Soc Med, July 1, 2008; 101(Supplement_1): 2 - 5. [Full Text] [PDF]

				C. H Goss and J. L Burns Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis Thorax, April 1, 2007; 62(4): 360 - 367. [Abstract] [Full Text] [PDF]

				M. E. Falagas, P. K. Koletsi, and I. A. Bliziotis The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol., December 1, 2006; 55(Pt 12): 1619 - 1629. [Abstract] [Full Text] [PDF]

				E. P. Judge, J. D. Dodd, J. B. Masterson, and C. G. Gallagher Pulmonary Abnormalities on High-Resolution CT Demonstrate More Rapid Decline Than FEV1 in Adults With Cystic Fibrosis. Chest, November 1, 2006; 130(5): 1424 - 1432. [Abstract] [Full Text] [PDF]

				R. Saginur, M. StDenis, W. Ferris, S. D. Aaron, F. Chan, C. Lee, and K. Ramotar Multiple Combination Bactericidal Testing of Staphylococcal Biofilms from Implant-Associated Infections Antimicrob. Agents Chemother., January 1, 2006; 50(1): 55 - 61. [Abstract] [Full Text] [PDF]

				S. M. Moskowitz, J. M. Foster, J. C. Emerson, R. L. Gibson, and J. L. Burns Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection J. Antimicrob. Chemother., November 1, 2005; 56(5): 879 - 886. [Abstract] [Full Text] [PDF]

				D. Hill, B. Rose, A. Pajkos, M. Robinson, P. Bye, S. Bell, M. Elkins, B. Thompson, C. MacLeod, S. D. Aaron, et al. Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions J. Clin. Microbiol., October 1, 2005; 43(10): 5085 - 5090. [Abstract] [Full Text] [PDF]

				J. E. Foweraker, C. R. Laughton, D. F. J. Brown, and D. Bilton Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing J. Antimicrob. Chemother., June 1, 2005; 55(6): 921 - 927. [Abstract] [Full Text] [PDF]

				S P Conway Nebulized antibiotic therapy: the evidence Chronic Respiratory Disease, January 1, 2005; 2(1): 35 - 41. [Abstract] [PDF]

				B. C. Marshall Pulmonary Exacerbations in Cystic Fibrosis: It's Time to Be Explicit! Am. J. Respir. Crit. Care Med., April 1, 2004; 169(7): 781 - 782. [Full Text] [PDF]

				R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]

				S. D. Aaron, W. Ferris, K. Ramotar, K. Vandemheen, F. Chan, and R. Saginur Single and Combination Antibiotic Susceptibilities of Planktonic, Adherent, and Biofilm-Grown Pseudomonas aeruginosa Isolates Cultured from Sputa of Adults with Cystic Fibrosis J. Clin. Microbiol., November 1, 2002; 40(11): 4172 - 4179. [Abstract] [Full Text] [PDF]

				J. B. Lyczak, C. L. Cannon, and G. B. Pier Lung Infections Associated with Cystic Fibrosis Clin. Microbiol. Rev., April 1, 2002; 15(2): 194 - 222. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594. [Full Text] [PDF]